Beauty Health (NASDAQ:SKIN – Get Free Report) and Biodesix (NASDAQ:BDSX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.
Volatility & Risk
Beauty Health has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
Profitability
This table compares Beauty Health and Biodesix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beauty Health | -3.87% | -19.70% | -1.97% |
| Biodesix | -49.31% | -504.41% | -43.94% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beauty Health | 2 | 4 | 1 | 0 | 1.86 |
| Biodesix | 1 | 1 | 4 | 0 | 2.50 |
Beauty Health currently has a consensus target price of $2.40, suggesting a potential upside of 58.42%. Biodesix has a consensus target price of $32.50, suggesting a potential upside of 192.27%. Given Biodesix’s stronger consensus rating and higher possible upside, analysts plainly believe Biodesix is more favorable than Beauty Health.
Insider & Institutional Ownership
93.3% of Beauty Health shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 41.0% of Beauty Health shares are owned by insiders. Comparatively, 30.1% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Beauty Health and Biodesix”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beauty Health | $334.30 million | 0.58 | -$29.10 million | ($0.22) | -6.89 |
| Biodesix | $71.32 million | 1.24 | -$42.93 million | ($5.56) | -2.00 |
Beauty Health has higher revenue and earnings than Biodesix. Beauty Health is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.
Summary
Beauty Health beats Biodesix on 9 of the 14 factors compared between the two stocks.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
About Biodesix
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Receive News & Ratings for Beauty Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beauty Health and related companies with MarketBeat.com's FREE daily email newsletter.
